a Department of Neurosurgery , Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA.
Expert Opin Biol Ther. 2019 Aug;19(8):845-854. doi: 10.1080/14712598.2019.1614557. Epub 2019 May 13.
With the approval of talimogene laherparepvec (T-VEC) for advanced malignant melanoma, virotherapy using oncolytic herpes simplex virus (oHSV) is now emerging as a viable therapeutic option for cancer patients, including malignant gliomas.
This review summarizes the most recent literature to provide cutting-edge knowledge about preclinical and clinical development of oHSV therapy for malignant gliomas, presenting current approaches to overcome obstacles to successful clinical application of oHSV in neuro-oncology.
Current strategies to improve the efficacy of oHSV therapy include engineering new viruses, modulation of innate and adaptive immune responses, combination with other treatments, and developing new oHSV delivery. All of these could rapidly be translated into clinical investigations, following several clinical trials that are currently ongoing.
随着替莫唑胺（T-VEC）获准用于晚期恶性黑色素瘤，溶瘤单纯疱疹病毒（oHSV）的病毒疗法现已成为癌症患者（包括恶性神经胶质瘤）的可行治疗选择。
本文综述了最新文献，提供了有关 oHSV 治疗恶性神经胶质瘤的临床前和临床开发的最新知识，介绍了克服 oHSV 在神经肿瘤学中成功临床应用障碍的当前方法。
目前提高 oHSV 治疗效果的策略包括工程新病毒、调节先天和适应性免疫反应、与其他治疗方法联合以及开发新的 oHSV 递药系统。所有这些策略都可能在目前正在进行的几项临床试验之后迅速转化为临床研究。
